Sotera Health (NASDAQ:SHC) Updates FY24 Earnings Guidance

Sotera Health (NASDAQ:SHC) updated its FY24 earnings guidance on Tuesday. The company provided EPS guidance of $0.67-0.75 for the period, compared to the consensus EPS estimate of $0.72. The company issued revenue guidance of $1.09-1.11 billion, compared to the consensus revenue estimate of $1.11 billion. Sotera Health also updated its FY 2024 guidance to 0.670-0.750 EPS.

Sotera Health Stock Performance

Sotera Health stock traded down $0.28 during mid-day trading on Thursday, hitting $15.83. 1,349,204 shares of the company’s stock traded hands, compared to its average volume of 1,307,183. Sotera Health has a one year low of $10.71 and a one year high of $17.44. The company has a market cap of $4.48 billion, a PE ratio of 63.40 and a beta of 2.08. The firm has a 50 day moving average price of $15.96 and a 200 day moving average price of $13.69. The company has a quick ratio of 2.59, a current ratio of 2.93 and a debt-to-equity ratio of 5.46.

Sotera Health (NASDAQ:SHC) last issued its quarterly earnings data on Tuesday, November 5th. The company reported $0.17 earnings per share for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01). The company had revenue of $285.47 million for the quarter, compared to the consensus estimate of $278.64 million. Sotera Health had a net margin of 3.65% and a return on equity of 47.26%. Sotera Health’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.18 earnings per share. On average, equities analysts forecast that Sotera Health will post 0.64 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Citigroup lifted their target price on Sotera Health from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday. Royal Bank of Canada reaffirmed an “outperform” rating and set a $17.00 target price on shares of Sotera Health in a research report on Tuesday, August 6th. Finally, Barclays increased their price target on Sotera Health from $14.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, August 6th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, Sotera Health presently has a consensus rating of “Moderate Buy” and an average price target of $16.50.

Insider Buying and Selling at Sotera Health

In related news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of the stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $15.03, for a total value of $150,300,000.00. Following the completion of the sale, the director now directly owns 49,215,301 shares of the company’s stock, valued at approximately $739,705,974.03. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 55.12% of the company’s stock.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.